CSF1R(+) macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype

Cited by (224)

Items 101–200 of 224

1. CSF1R-Expressing Tumor-Associated Macrophages, Smoking and Survival in Lung Adenocarcinoma: Analyses Using Quantitative Phosphor-Integrated Dot Staining
   Kentaro Inamura, Yasuyuki Shigematsu, Hironori Ninomiya, Yasuhiro Nakashima, Maki Kobayashi, Haruyuki Saito, Katsuhiro Takahashi, Etsuko Futaya, Sakae Okumura, Yuichi Ishikawa et al. · 2018 · Cancers
2. Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease
   Dea Filippini, Sabrina L. D’Agosto, Pietro Delfino, Michele Simbolo, Geny Piro, Borislav Chavdarov Rusev, Lisa Veghini, Cinzia Cantù, Francesca Lupo, Stefano Ugel et al. · 2019 · Scientific Reports
3. Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC
   Francesca Lupo, Francesco Pezzini, Davide Pasini, Elena Fiorini, Annalisa Adamo, Lisa Veghini, Michele Bevere, Cristina Frusteri, Pietro Delfino, Sabrina L. D’Agosto et al. · 2024 · Gut
4. Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)
   Paolo A. Ascierto, Carlo Bruno Bifulco, Luigi Buonaguro, Leisha A. Emens, Robert Louis Ferris, Bernard A. Fox, Greg M. Delgoffe, Jérôme Galon, Cesare Gridelli, Marco Carlo Merlano et al. · 2019 · Journal for ImmunoTherapy of Cancer
5. Induced CD10 expression during monocyte-to-macrophage differentiation identifies a unique subset of macrophages in pancreatic ductal adenocarcinoma
   Xin Huang, Chaobin He, Guo‐He Lin, Lianghe Lu, Kaili Xing, Xin Hua, Shuxin Sun, Yize Mao, Yunda Song, Jun Wang et al. · 2020 · Biochemical and Biophysical Research Communications
6. Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives
   Koji Miyabayashi, Hayato Nakagawa, Kazuhiko Koike · 2021 · Frontiers in Oncology
7. Potential role of p53 deregulation in modulating immune responses in human malignancies: A paradigm to develop immunotherapy
   Shivi Chauhan, Shivani Jaiswal, Vibhuti Jakhmola, Bhavana Pendurthi Singh, Sujata Bhattacharya, Manoj Garg, Shinjinee Sengupta · 2024 · Cancer Letters
8. A Spontaneous Aggressive ERα+ Mammary Tumor Model Is Driven by Kras Activation
   Katie Marie Campbell, Kathleen A. O’Leary, Debra E. Rugowski, William A. Mulligan, Erica Kay Barnell, Zachary L. Skidmore, Kilannin Krysiak, Malachi Griffith, Linda A. Schuler, Obi L. Griffith · 2019 · Cell Reports
9. USP14-IMP2-CXCL2 axis in tumor-associated macrophages facilitates resistance to anti-PD-1 therapy in gastric cancer by recruiting myeloid-derived suppressor cells
   Li You, Qian Wang, Tianxue Zhang, Hongwei Xiao, Mengjiao Lv, Hong Lv, Li Deng, Xuyao Zhang, Yu Zhang · 2025 · Oncogene
10. Cancer‐Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets
    Yutao Li, Qingyun Liu, Xilin Jing, Yuqi Wang, Xiaohua Jia, Xing Yang, Kezhong Chen · 2025 · MedComm
11. Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance
    Thatcher Ross Heumann, Nilofer Saba Azad · 2021 · Cancer and Metastasis Reviews
12. Precision treatment of pancreatic ductal adenocarcinoma
    Hongyun Wei, He Ren · 2024 · Cancer Letters
13. Metastatic heterogeneity in pancreatic cancer: mechanisms and opportunities for targeted intervention
    Ravikanth Maddipati · 2025 · Journal of Clinical Investigation
14. An Immunological Glance on Pancreatic Ductal Adenocarcinoma
    Michael Karl Melzer, Frank Arnold, Katja Stifter, Friedemann Zengerling, Ninel Azoitei, Thomas Theodor Werner Seufferlein, Christian Bolenz, Alexander Kleger · 2020 · International Journal of Molecular Sciences
15. HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells
    Katharina M. Ewers, Shilpa Patil, Waltraut Kopp, Jürgen Thomale, Tabea Quilitz, Anna Magerhans, Xin Wang, Elisabeth Heßmann, Matthias Dobbelstein · 2021 · Cancers
16. DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer
    Anna I. Brichkina, Miriam Ems, Roman Vladimirovich Suezov, Rajeev Singh, Veronika Lutz, Felix S.R. Picard, Andrea Nist, Thorsten Stiewe, Johannes Graumann, Michael Daude et al. · 2024 · Gut
17. Impact of anatomic site on antigen-presenting cells in cancer
    Maria Zagorulya, Ellen Duong, Stefani Spranger · 2020 · Journal for ImmunoTherapy of Cancer
18. PD-1/PD-L1–Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups
    Eva Karamitopoulou, Andreas Andreou, Aurélie Pahud de Mortanges, Marianne Tinguely, Beat Gloor, Aurel Perren · 2021 · Cancer Immunology Research
19. Therapeutic Potential of Targeting Stromal Crosstalk-Mediated Immune Suppression in Pancreatic Cancer
    Wenting Du, Marina Pasca di Magliano, Yaqing Zhang · 2021 · Frontiers in Oncology
20. Mutant p53 as an Antigen in Cancer Immunotherapy
    Navid Sobhani, Alberto D’Angelo, Xu Wang, Ken H. Young, Daniele Generali, Yong Li · 2020 · International Journal of Molecular Sciences
21. Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy
    Jing Zhou, Yuexu Jiang, Yue Huang, Qiongling Wang, Jussuf T. Kaifi, Eric T. Kimchi, Chiswili Yves Chabu, Zhenguo Liu, Trupti Joshi, Guangfu Li · 2021 · Translational Oncology
22. Inhibition of HCK in myeloid cells restricts pancreatic tumor growth and metastasis
    Ashleigh R. Poh, Megan O’Brien, David Chisanga, Hong He, David Baloyan, Jasmin Traichel, Christine Dijkstra, Michaël Chopin, Stephen L. Nutt, Lachlan W. Whitehead et al. · 2022 · Cell Reports
23. Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma
    Wei Zhang, Xi Jiang, Youcheng Zou, Lihua Yuan, Xiaobo Wang · 2023 · Frontiers in Pharmacology
24. KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma
    Minh T. Than, Mark H. O’Hara, Ben Z. Stanger, Kim A. Reiss · 2024 · Molecular Cancer Therapeutics
25. Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance
    Reham Ajina, Zoe X. Malchiodi, Allison A. Fitzgerald, Annie Zuo, Shangzi Wang, Maha Moussa, Connor J. Cooper, Yue Liang Shen, Quentin R. Johnson, Jerry M. Parks et al. · 2021 · Cancer Immunology Research
26. Deconstructing Pancreatic Cancer Using Next Generation-Omic Technologies–From Discovery to Knowledge-Guided Platforms for Better Patient Management
    Daniel Schreyer, John P. Neoptolemos, Simon T. Barry, Peter Bailey · 2022 · Frontiers in Cell and Developmental Biology
27. Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment
    Jesús Amo‐Aparicio, Adrian T.A. Dominguez, Shaikh Muhammad Atif, Alberto Dinarello, Tania Azam, Kibrom M. Alula, Miles Piper, Christopher Hanyoung Lieu, Robert William Lentz, Alexis Diane Leal et al. · 2023 · Cancer Research Communications
28. Stromal Cells Promote Matrix Deposition, Remodelling and an Immunosuppressive Tumour Microenvironment in a 3D Model of Colon Cancer
    Niamh A. Leonard, Eileen Reidy, Kerry Thompson, Emma A. McDermott, Eleonora Peerani, Elena Tomás Bort, Frances R. Balkwill, Daniela Loessner, Aideen E. Ryan · 2021 · Cancers
29. Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception
    Sharia D. Hernandez, Edwin Roger Parra, Naohiro Uraoka, Ximing Tang, Yu Shen, Wei Qiao, Mei Jiang, Shanyu Zhang, Barbara Mino, Wei Lü et al. · 2022 · Clinical Cancer Research
30. Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer
    Adam S. Bryce, Stephan B. Dreyer, Fieke E. M. Froeling, David Kuang-Fu Chang · 2022 · Cancers
31. Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma
    Huey-Jen L. Lin, Yingguang Liu, Kailey P. Caroland, Jiayuh Lin · 2023 · Cancers
32. Pancreatic Cancer: From Genome Discovery to PRECISION-Panc
    Stephan B. Dreyer, Nigel Balfour Jamieson, Jennifer P. Morton, Owen James Sansom, Andrew Victor Biankin, David Kuang-Fu Chang · 2019 · Clinical Oncology
33. Treatment With the CSF1R Antagonist GW2580, Sensitizes Microglia to Reactive Oxygen Species
    Katiria Soto‐Díaz, M. Vailati-Riboni, Allison Y. Louie, Daniel B. McKim, H. Rex Gaskins, Rodney W. Johnson, Andrew J. Steelman · 2021 · Frontiers in Immunology
34. Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival
    Peter J. Bailey, Xu Zhou, Jingyu An, Teresa Peccerella, Kai Hu, Christoph Springfeld, Markus Wolfgang Büchler, John P. Neoptolemos · 2023 · Function
35. Prkci Regulates Autophagy and Pancreatic Tumorigenesis in Mice
    Kristin S. Inman, Yi Liu, Michele L. Scotti, Michael Leitges, Murli Krishna, Howard C. Crawford, Alan P. Fields, Nicole R. Murray · 2022 · Cancers
36. Emerging Prognostic and Predictive Factors in Pancreatic Cancer
    Eva Karamitopoulou · 2023 · Modern Pathology
37. Molecular subclassification of gastrointestinal cancers based on cancer stem cell traits
    Meimei Li, Jun Yuan, Xin‐Yuan Guan, Ning‐Fang Ma, Ming Liu · 2021 · Experimental Hematology and Oncology
38. Targeting myeloid cells in pancreatic ductal adenocarcinoma: from primary tumors to liver metastasis
    Ruining Gong, Ying Chen, David Kuang-Fu Chang, Huan Zhang, Zimin Liu, Qian Yu · 2025 · Frontiers in Immunology
39. Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC
    Carlotta Cattolico, Peter Bailey, Simon T. Barry · 2022 · Frontiers in Cell and Developmental Biology
40. Decoding the microbial blueprint of pancreatic cancer
    Jhommara Bautista, Ricardo Bedón-Galarza, Francisco Martínez-Hidalgo, Martina Jared Masache-Cruz, Melanie Benítez-Núñez, Camila Valencia-Arroyo, Andrés López‐Cortés · 2026 · Frontiers in Medicine
41. Immunomodulation in Pancreatic Cancer
    Mithunah Krishnamoorthy, John Gordon Lenehan, Jeremy P. Burton, Saman Maleki Vareki · 2020 · Cancers
42. Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma
    Julia R. Naso, James Thomas Topham, Joanna M. Karasinska, Michael K.C. Lee, Steve E. Kalloger, Hui‐Li Wong, Jessica Nelson, Richard A. Moore, Andrew J. J. Mungall, Steven J.M. Jones et al. · 2020 · Cancer Medicine
43. Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment
    Frank Arnold, Annachiara Del Vecchio, Zainab Hussain, Mara H. Sherman · 2026 · Nature reviews. Cancer
44. Targeting sphingosine 1-phosphate and sphingosine kinases in pancreatic cancer: mechanisms and therapeutic potential
    Khem Raj Limbu, Rashmi Bhandari Chhetri, Su-Bin Kim, Jitendra Shrestha, Yoon Sin Oh, Dong Jae Baek, Eun‐Young Park · 2024 · Cancer Cell International
45. The Achilles’ Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials
    Despina Siolas, C. Morrissey, Paul E. Oberstein · 2020 · Journal of Pancreatology
46. High SALM3 Expression in Tumor Cells and Fibroblasts Is Correlated with Poor Prognosis in Gastric Cancer Patients
    Ying Liu, Xiaoli Chen, Xi Chen, Xiaobing Yang, Qingjie Song, Han Jiang Wu · 2019 · Disease Markers
47. Single-Cell Analysis of Chemotherapy-induced Remodeling Reveals CD276-driven Basal-like Chemoresistance in Pancreatic Cancer
    Yao Zhang, Yanhua Du, Jiaxin Wang, Danshu Wang, Judong Li, Jing Zhang, Yizhou Zhao, Sishen Sun, Hongxiang Sun, Jingjing Qi et al. · 2026 · Gastroenterology
48. Molecular Pathology of Pancreatic Cancer
    Eva Karamitopoulou · 2022 · Cancers
49. Could Protons and Carbon Ions Be the Silver Bullets Against Pancreatic Cancer?
    Camille Huart, Jiawei Chen, Benjamin Le Calvé, Carine Michiels, Anne-Catherine Wéra · 2020 · International Journal of Molecular Sciences
50. Angiogenesis and Pancreatic Cancer: Novel Approaches to Overcome Treatment Resistance
    C.J. Grobbelaar, Mpho Klaas Kgomo, Peace Mabeta · 2024 · Current Cancer Drug Targets
51. Tumor heterogeneity: An oncogenic driver of PDAC progression and therapy resistance under stress conditions
    António M. Palma, Vignesh Vudatha, Maria Leonor Peixoto, Esha Madan · 2023 · Advances in cancer research
52. Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC
    Chiara Musiu, Francesca Lupo, Antonio Agostini, Gabriella Lionetto, Michele Bevere, Salvatore Paiella, Carmine Carbone, Vincenzo Corbo, Stefano Ugel, Francesco De Sanctis · 2024 · Frontiers in Immunology
53. A Tumor Progression Related 7-Gene Signature Indicates Prognosis and Tumor Immune Characteristics of Gastric Cancer
    Fen Liu, Zongcheng Yang, Lixin Zheng, Wei Shao, Xiujie Cui, Yue Wang, Jihui Jia, Yue Fu · 2021 · Frontiers in Oncology
54. Pancreatic ductal adenocarcinoma holds unique features to form an immunosuppressive microenvironment: a narrative review
    Qiang Zhou, Dan Chen, Junfeng Zhang, Ji-Feng Xiang, Tao Zhang, Huaizhi Wang, Yanyan Zhang · 2022 · Journal of Pancreatology
55. The heterogeneity of CAFs and immune cell populations in the tumor microenvironment of pancreatic adenocarcinoma
    Maria Diab, Bassel F. El‐Rayes · 2022 · Journal of Cancer Metastasis and Treatment
56. Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma
    Pooyeh Farahmand, Katarína Gyurászová, Claire Rooney, Ximena L. Raffo Iraolagoitia, Geeshath Jayasekera, Ann Hedley, Emma R. Johnson, Tatyana Chernova, Gaurav Malviya, H. G. HALL et al. · 2023 · Frontiers in Toxicology
57. Mechanisms Underlying Tumor-Associated Macrophages (TAMs)-Facilitated Metastasis
    Elahe Aleebrahim‐Dehkordi, Niloofar Deravi, Mohammad Sadegh Fallahi, Nima Rezaei · 2023 · Springer eBooks
58. The potential application of stroma modulation in targeting tumor cells: Focus on pancreatic cancer and breast cancer models
    Giuseppina Roscigno, S. Jacobs, Belén Toledo, Roberto Borea, Gianluca Russo, Francesco Pepe, María José Serrano, Viola Calabrò, Giancarlo Troncone, Roberto Giovannoni et al. · 2025 · Seminars in Cancer Biology
59. In situ multi-modal characterization of pancreatic cancer reveals tumor cell identity as a defining factor of the surrounding microenvironment
    Anna Lyubetskaya, Brian A. Rabe, Andrew J. Kavran, Yulong Bai, Andrew Fisher, Alba Font‐Tello, Anne C. Lewin, Hannah A. Pliner, Yunfan Fan, Lauren Giampapa et al. · 2026 · Cell Reports
60. Tumour-associated myeloid cells expressing IL-10R2/IL-22R1 as a potential biomarker for diagnosis and recurrence of pancreatic ductal adenocarcinoma
    Hyung Keun Lee, So Young Kim, Soo-Hyun Chung, Bongkun Choi, Ji-Eun Kim, Dohee Yoon, Sung Ill Jang, Areum Yeo, Hyun Goo Kang, Jusung Lee et al. · 2024 · British Journal of Cancer
61. Pancreatic Adenocarcinoma Invasiveness and the Tumor Microenvironment: From Biology to Clinical Trials
    Isabel Mejia, Sandhya Bodapati, Kathryn T. Chen, Begoña Díaz · 2020 · Biomedicines
62. New avenues for the treatment of immunotherapy-resistant pancreatic cancer
    Luis Guilherme de Oliveira Silva, Fabian Fellipe Bueno Lemos, Marcel Silva Luz, Samuel Luca Rocha Pinheiro, Mariana Santos Calmon, Gabriel Lima Correa Santos, Gabriel Reis Rocha, Fabrício Freire de Melo · 2024 · World Journal of Gastrointestinal Oncology
63. Hear Pancreatic Cancer Stem Cells ROR
    Wantong Yao, Anirban Maitra · 2019 · Cell
64. Using Single Cell Transcriptomics to Elucidate the Myeloid Compartment in Pancreatic Cancer
    Padma Kadiyala, Ahmed M. Elhossiny, Eileen S. Carpenter · 2022 · Frontiers in Oncology
65. The genomic landscape of the immune system in lung cancer: present insights and continuing investigations
    Mina Roshan Zamir, Aida Khademolhosseini, Kavi Rajalingam, Abbas Ali Ghaderi, Raja Rajalingam · 2024 · Frontiers in Genetics
66. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma
    Ri-Lan Bai, Nan-Ya Wang, Lingling Zhao, Yong‐Fei Zhang, Jiuwei Cui · 2021 · Hepatobiliary & pancreatic diseases international
67. Perioperative immunotherapy for pancreatic cancer is on its way
    Christoph Springfeld, Peter J. Bailey, Thilo Hackert, John P. Neoptolemos · 2021 · HepatoBiliary Surgery and Nutrition
68. Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
    Meredith L. Stone, Veronica M. Herrera, Yan Li, Heather Coho, Yuqing Xue, Kathleen K. Graham, Jennifer Ratmansky, Devora Delman, Shaun O’Brien, Gregory Lawrence Beatty · 2025 · Cancer Immunology Research
69. The BRD4 Inhibitor I-BET-762 Reduces HO-1 Expression in Macrophages and the Pancreas of Mice
    Ana S. Leal, Karen T. Liby · 2024 · International Journal of Molecular Sciences
70. Comprehensive analysis of the effects of KIF2C on prognosis, biological functions and immune infiltration in PAAD
    Jianghui Xiong, Rongshou Wu, Aoxiao He, Ping Hou, Jiakun Wang, Rongguiyi Zhang, Wenjun Liao, Linquan Wu, Enliang Li · 2022 · Tissue and Cell
71. Dynamic crosstalk between tumor-associated macrophages and cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
    Jinping Zhang, Dandan Zhang, Xun Liu, Mengdie Xu, Jin‐Wei He, Jing Ma, Zhihui Yang · 2025 · Critical Reviews in Oncology/Hematology
72. Neuro-tumor-immune crosstalk in pancreatic cancer: Mechanisms and therapeutic insights.
    Jian-Guo Jin, Bin He, Xiang Wang, Yuqian Zhang, Huiming You, Sirui Mo, Duancheng Guo, Saimeng Shi · 2026 · Biochimica et biophysica acta. Reviews on cancer
73. A novel three-dimensional co-culture model for studying exosome-mediated cell interactions in glioblastoma
    Kaishu Li, Siyuan Du, Haichao Li, Zhaohui Li, Qihui Zhu, Qian Peng, Baojian Liao, Ling Qi · 2025 · Biochimica et Biophysica Acta (BBA) - General Subjects
74. Tumor lineage-specific immune response in brain metastatic disease: opportunities for targeted immunotherapy regimen?
    Shiva Najjary, Johan M. Kros, Willem de Koning, Disha Vadgama, Karishma A. Lila, Janina L Wolf, Dana A. M. Mustafa · 2023 · Acta Neuropathologica Communications
75. Epigenetic and transcriptional control of classical and basal-like cell states in pancreatic ductal adenocarcinoma
    Christina Parassiadis, Steven A. Johnsen · 2026 · Gastroenterology report
76. Macrophage proliferation machinery leads to PDAC progression, but susceptibility to innate immunotherapy
    Chong Zuo, John M. Baer, Brett L. Knolhoff, Jad I. Belle, Xiuting Liu, Graham D. Hogg, Christina F. Fu, Natalie L. Kingston, Marcus A. Brenden, Angela Alarcon de la Lastra et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
77. Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation
    Tiantong Liu, Sihang Cheng, Qiang Xu, Zhiwei Peter Wang · 2022 · Medicina
78. WNT7B drives a program for pancreatic cancer subtype switching and progression
    Joep Sprangers, Jeroen M. Bugter, Despina Xanthakis, Michiel Boekhout, Rutger N.U. Kok, Veerle Geurts, Hans C. Clevers, Lodewijk A.A. Brosens, Frederike Dijk, Maria J. Rodríguez Colman et al. · 2026 · iScience
79. Immunotherapy for Pancreatic Cancer
    Yoshiaki Sunami, Simon Rieder, Patrick Michl, Jorg H. Kleeff · 2023 · Springer eBooks
80. Immuno-Oncology in Pancreatic Cancer
    Nigel Balfour Jamieson, Colin William Steele · 2021 · Springer eBooks
81. Therapeutic Implications of UVB Irradiation in Cancer by Enhancing Anti‐Tumor Immunity†
    Bilal Bin Hafeez, Ed Wong Alvarado, Dae Joon Kim · 2022 · Photochemistry and Photobiology
82. Immunotherapy for Pancreatic Cancer
    Yoshiaki Sunami, Simon Rieder, Patrick Michl, Jorg H. Kleeff · 2025 · Springer eBooks
83. Targeting tumor-associated macrophages in pancreatic cancer
    Yuxi Long, Luoyingzi Xie, Fuming Xie, Xianxing Wang, Huaizhi Wang, Tian Yang, Lei Cai · 2026 · iLiver
84. Driving tumor-associated macrophages to a CXCL9Hi/SPP1Low phenotype eliminates pancreatic cancer
    Yen Thi Minh Nguyen, Marc Pfefferlé, Juhyun Oh, G. G. Simpson, S. A. Walker, Shingo Noguchi, Christopher S. Garris, Riley J. Deutsch-Williams, P. Wirapati, Federico De Stefano et al. · 2026 · Cell Reports Medicine
85. Reprogramming tumor-associated macrophages and interferon-gamma signaling to overcome therapeutic resistance in cancer
    Hongmei Li, Xiaoqiang Dai · 2026 · Pathology - Research and Practice
86. A shifting adversary: control of pancreatic cancer transcriptomic subtypes
    Charles J. David · 2022 · Journal of Cancer Metastasis and Treatment
87. PDAC Subtypes/Stratification
    Holly Brunton, Giuseppina Caligiuri, Gareth J. Inman, Peter J. Bailey · 2020 · Molecular and translational medicine
88. Molecular Subtyping of Pancreatic Cancer
    Stephan B. Dreyer, Nigel Balfour Jamieson, David Kuang-Fu Chang, Andrew Victor Biankin · 2021 · Springer eBooks
89. MAP Kinase inhibition reshapes tumor microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages
    Pietro Delfino, Christian Neander, Dea Filippini, Sabrina L. D’Agosto, Caterina Vicentini, Elena Fiorini, Francesca Lupo, Claudia Fiorini, Borislav Chavdarov Rusev, Gael D. Temgue Tane et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
90. Targeting Myeloid Protein Kinase C Signaling to Overcome Immune Suppression and Improve Immunotherapy in Cancer
    Mehdi Chaib · 2022
91. Macrophage reprogramming—rather than depletion—is efficacious in a specific subset of colorectal tumor models
    Noha-Ehssan Mohamed, Raheleh Amirkhah, Xabier-Cortes Lavaud, Kathryn L. Gilroy, Robin Bartolini, Eoghan J. Mulholland, Abhishek Dinkarnath Garg, Kathryn A.F. Pennel, René Jackstadt, Rachel A. Ridgway et al. · 2023 · Research Square
92. Combination Immunotherapy Enhances Serial Radiofrequency Ablation Induced Systemic Antitumor Immunity in Pancreatic Cancer
    Lincoln N. Strickland, MacKenzie V. Demmel, Wendao Liu, AR Waller, Shwetapadma Dash, Khadija Shahab Turabi, Urvinder Kaur Sardarni, Nicolette R. Mardik, Casey Van Kirk, Baylee J. O’Brien et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
93. Intratumoral STING Activation Sensitizes Poorly Immunogenic Cancers to Checkpoint Blockade Immunotherapy
    Casey R. Ager · 2018 · Digital Commons-TMC (Texas Medical Center)
94. Immune Selection Pressure Contributes to Pancreatic Cancer Immune Evasion
    Reham Ajina, Annie Zuo, Shangzi Wang, Maha Moussa, Connor J. Cooper, Yue Liang Shen, Quentin R. Johnson, Jerry M. Parks, Jeremy C. Smith, Marta Catálfamo et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
95. Improvement of a 3D model system for the evaluation and treatment of pancreatic ductal adenocarcinoma
    Robert Gudmund Oppedal Willoughby · 2021 · NORA - Norwegian Open Research Archives
96. Overcoming Cisplatin Resistance in Pancreatic Cancer
    Katharina M. Ewers · 2021
97. Modeling Resistance to Immune Checkpoint Blockade
    Michael M. Quigley, Matthew J. Meyer, Kanstantsin V. Katlinski · 2022 · Wiley eBooks
98. In-vitro- und In-vivo-Untersuchungen zum Gemcitabinmetabolismus von Makrophagen im Duktalen Adenokarzinom des Pankreas
    Sören Matthias Buchholz · 2022
99. Molecular Biology, Genetics, and Translational Models of Human Cancer
    Benno Traub, Florian Scheufele, Srinivas Raghavan Viswanathan, Matthew M. Meyerson, David A. Tuveson · 2022 · Wiley eBooks
100. Identification of circulating myeloid cells as a potential diagnosis and recurrence marker of pancreatic ductal adenocarcinoma through the single-cell analysis
     Hyung Keun Lee, So Young Kim, Soo-Hyun Chung, Bongkun Choi, Sung Ill Jang, Arum Yoi, Hyun Goo Kang, Jusung Lee, Yoon Ha Choi, Joon Seong Park et al. · 2022 · Research Square